I wonder if the devs have pivoted at all with Lady Dimitrescu?
There you have it, Shacknews, your Evening Reading for tonight. Please consider subscribing to Shacknews Mercury to support our site for as little as $1/month.
Here s a photo of Rad cleaning his toe beans.
What are you up to tonight? Let us know in the Shacknews Chatty comment thread below.
Guides Editor
Hailing from the land down under, Sam Chandler brings a bit of the southern hemisphere flair to his work. After bouncing round a few universities, securing a bachelor degree, and entering the video game industry, he s found his new family here at Shacknews as a Guides Editor. There s nothing he loves more than crafting a guide that will help someone. If you need help with a guide, or notice something not quite right, you can Tweet him: @SamuelChandler
How CRISPR might help diagnose and halt dangerous outbreaks faster yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Results for
US-Israeli VC firm NFX launches new Biotech fund
NFX launches NFX Bio: a new investment arm that will finance pre-seed and Seed rounds of Israeli and American biotech companies. Yaneev Avital / 3 Feb 2021 • 1 min read
NFX, an Israeli-American venture capital firm that focuses on pre-seed and Seed investments, announced the launch of NFX Bio - the new investment arm led by Venture Partner Dr. Omri Amirav Drory. Founder and CEO of Twist Bioscience, Emily Leproust Ph.D., will join the NFX Bio team as an advisor.
Synthetic DNA funding
According to the VC fund’s announcement, NFX Bio will continue the pre-seed and Seed investment focus. Although just recently announced, the fund has already invested in a number of companies, including Twist Bioscience - a synthetic DNA producer founded in 2013, and is currently traded at $8.5 billion; and
DARPA to Fund CRISPR Diagnostics Using Mammoth, IDbyDNA Technologies
January 18, 2021
Mammoth Biosciences will apply its DETECTR™ platform, and IDbyDNA its proprietary pathogen database and algorithms, toward the development of CRISPR-based diagnostics and biosurveillance technologies against infectious disease threats for the U.S. Department of Defense (DoD). [Source: MR.Cole Photographer / Moment / Getty Images]
Share
Mammoth Biosciences will apply its DETECTR™ platform, and IDbyDNA, its proprietary pathogen database and algorithms, toward the development of CRISPR-based diagnostics and biosurveillance technologies against varied disease threats for the U.S. Department of Defense (DoD).
Mammoth and IDbyDNA are among subcontractors under a four-year, up-to-$36.7 million CRISPR diagnostics contract inked by DoD’s Defense Advanced Research Projects Agency (DARPA) with prime contractor MRIGlobal.